I feel a lot better today after the dr been interview last night and the 2nd PR further explaining the situation. It is clear leronlimab works is a broad spectrum of patients. This is huge info, this drug is not specific to a narrow symptom or patient condition, it works. The problem is that we had too small of a trial and the wrong PE. Many here have raised the concern about the arbitrary 28 day mortality and its problems. Few here realized (including myself) that when you have a relatively small trial, the range of patient recruitment leads to in related comparisons and making it difficult to present a conclusive apples to apples assessment. If this was a 1000+ patient trial, we would not have the problem with too many over 65 on treatment and too few in placebo. We essentially have a phase 2 trial with a ton of solid data. Any way the data was sliced, leronlimab works. The fact that we might need to add 140 patients is extremely encouraging. It says the FDA gets it, they just need the trial to have a end conclusion that allows them to approve. They know the drug works. We also don’t know if this added protocol is even needed, the higher ups are looking at this and they are the ones to bend the rules. Nader is just following the rules.
If we had a larger trial that could lead to approval, we would be still enrolling today. With this data out, I think it will be easy to enroll. It will take a couple months, but we know it will work, there is no guessing.
Also, compare this situation to all other treatment options. Those trials had to be mined to get some showing of effectiveness. With CD12, no matter how you look at it the drug works, the trial design is the problem that prevents the P value. The extension is purely to fix the trial problem, not to twist the data to make a drug that does not work look like it does.
Let’s also keep in mind, the data is out, anyone from the medical community and the BP world can see this drug just proved it is not just an HIV drug. BP now has the luxury of approaching cytodyn knowing they both know what leronlimab can do. The very near term data from Nash and the cancer basket trial will really put the spotlight on this. The world does not need to understand, the industry now does.
Category: BusinessTotal Views: 97 By : EditorUpdated: 06-25-2024
SEC Charges Meta Materials Inc. and Former CEOs with Fraud
The SEC has filed fraud and other violation charges against Meta Materials Inc. and its former CEOs, John Brda and George Palikaras. These accusations are the product of a $137.5 million market manipulation scheme. The corporation has consented to have the charges settled through an administrative process. Federal district court will hear SEC's lawsuit against Brda and Palikaras. The accusations include breaching the provisions pe... Continue Reading
Category: EconomyTotal Views: 91 By : EditorUpdated: 06-25-2024
Overview of the Inflation Report for Friday
Understanding the state of the economy now depends critically on the inflation report that is due on Friday. The report will center on the Federal Reserve's preferred inflation indicator, the Personal Consumption Expenses (PCE) index. The inflation rates have been declining recently, and this report should offer more proof of the slowing down of price rises. Wall Street Journal and Dow Jones Newswires economists polled for May expect the PCE ind... Continue Reading
Court Rulings Halt Key Parts of Biden’s Student Loan Repayment Plan
The student loan repayment plan of President Joe Biden was recently put on hold by two federal judges. These rulings keep the Education Department from putting into effect important SAVE loan repayment program features that would lower monthly payments and wipe out millions of Americans' student debt. The court's decisions answered lawsuits brought by Republican-led states that contended the administration's... Continue Reading
Category: MarketsTotal Views: 92 By : EditorUpdated: 06-25-2024
Nasdaq Climbs 1.3% Led by Big Tech
Tuesday's 1.3% gain was notable for the Nasdaq Composite. Mainly, this increase was fueled by excellent results from big IT firms. Notable contributors were Nvidia and Alphabet, the latter of which set a record. Especially those in the artificial intelligence space, investors displayed a renewed confidence in tech stocks. This momentum helped the tech-heavy index outpace other significant U.S. stock indices. The power of the IT industry offered a strong ... Continue Reading
Category: Real EstateTotal Views: 100 By : EditorUpdated: 06-25-2024
Record-High Home Prices As Mortgage Rates Rise
Even as mortgage rates increased in April, home prices broke all previous records. The usual assumption that rising mortgage rates would drive down house prices is refuted by this odd trend. Prices rose 6.3% over the same month in the previous year, according to the S&P CoreLogic Case-Shiller National Home Price Index. This rise is the second month running that prices have increased significantly. An average 30-year fixed mortgage rate increa... Continue Reading
Category: MarketsTotal Views: 148 By : EditorUpdated: 06-25-2024
General Market Sentiment: Bullish Trends
With significant indices like the NASDAQ and S&P 500 exhibiting rising trends, the market has been generally bullish. Strong corporate earnings and encouraging economic data are the main causes of the high investor trust. The general good mood is being aided by the expansion of many sectors. The bullish tendency is a reflection of hope for corporate profitability and the economic recovery. The market is still strong in spite of certain difficulties... Continue Reading
Category: StocksTotal Views: 157 By : EditorUpdated: 06-25-2024
Investor popularity plays a pivotal function inside the achievement of commercial enterprise activities, in which establishing credibility and fostering significant connections are paramount. One innovative way to beautify investor engagement and networking effectiveness is through the strategic use of custom event badges. These badges no longer best serve as identifiers but also as powerful tools for branding, professionalism, and facilitating connections amongst members.
The Role of Custom ... Continue Reading
Category: BusinessTotal Views: 123 By : EditorUpdated: 06-25-2024
Kevin O'Leary Criticizes San Francisco's Decline
Popular from his time on "Shark Tank," Kevin O'Leary called San Francisco a "wasteland." He holds the decline of the city to bad political choices. San Francisco is no longer recognisably a part of America, claims O'Leary. He begs folks to come see the deterioration for themselves. O'Leary talked about it on "Cavuto: Coast to Coast." He emphasized the effects of unwelcome laws and high taxes. He... Continue Reading
Category: EconomyTotal Views: 204 By : EditorUpdated: 06-25-2024
U.S. Auto Sales are Predicted to Slow Down in the Second Half of 2024
Second-half 2024 is expected to see a slowdown in American auto sales. This comes after an impressive first half, when sales climbed 2.9% over the same period the previous year. A number of issues confronting the sector could impede its ongoing expansion. Potential problems are indicated by growing sales incentives and rising car inventory levels. Uncertainties in the economy, changes in interest rates, and the approaching ... Continue Reading
Category: EconomyTotal Views: 304 By : EditorUpdated: 06-25-2024
Fed Governor Michelle Bowman Open to Rate Hikes if Inflation Persists
If inflation doesn't go down, Federal Reserve Governor Michelle Bowman said she's still willing to raise interest rates. Bowman stressed in a speech in London that the data at this time does not yet support reducing rates. She underlined that rate reductions should wait until inflation approaches the Fed's 2% goal. Bowman is acting cautiously considering the ongoing inflationary pressures. She seems prepared to ... Continue Reading